✦ LIBER ✦

Pharmacokinetics, safety, and tolerability of flosequinan in patients with hepatic dysfunction

✍ Scribed by J. L. Hinson; I. D. Hind; D. J. Weidler

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 513 KB
Volume: 83
Category: Article
ISSN: 0022-3549
DOI: 10.1002/jps.2600830323

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetic profile of flosequinan i

Pharmacokinetic profile of flosequinan in patients with compromised renal function

✍ Bruno V. Gallo; James L. Hinson; Donald J. Weidler 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 472 KB

Recombinant human γ-interferon in patien

Recombinant human γ-interferon in patients with chronic active hepatitis B: Pharmacokinetics, tolerance and biological effects

✍ Patrick Marcellin; Marie-Anne Loriot; Nathalie Boyer; Michéle Martinot-Peignoux; 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 397 KB

Pharmacokinetics, tolerance and biological effects of human recombinant y-interferon were studied in 12 patients with chronic active hepatitis B. Serum concentrations of y-interferon were measured by radioimmunoassay in four patients after a subcutaneous injection of 10 million U (0.6 mg); the peak

A pharmacokinetic and tolerance study of

A pharmacokinetic and tolerance study of romazarit in patients with rheumatoid arthritis

✍ Dr P. E. O. Williams; H. A. Bird; S. Minty; P. S. Helliwell; G. J. Muirhead; J. 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 553 KB

Romazarit is a new drug for which animal pharmacology suggests a disease-modifying action in rheumatoid arthritis (RA). These animal studies predict that plasma romazarit concentrations within the range 50-100 mg I-' may be required for efficacy in the clinic. Therefore, a pharmacokinetic study was

Safety of hepatic resection in overweigh

Safety of hepatic resection in overweight and obese patients with cirrhosis

✍ A. Cucchetti; M. Cescon; G. Ercolani; P. Di Gioia; E. Peri; A. D. Pinna 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 2 views

## Abstract ## Background The simultaneous incremental increase in incidence of both obesity and hepatocellular carcinoma (HCC) will soon lead to more overweight and obese patients with cirrhosis needing surgery. At present, little is known about postoperative mortality and morbidity in such patie

Pharmacokinetic profiles of glycyrrhizin

Pharmacokinetic profiles of glycyrrhizin in patients with chronic hepatitis

✍ Naomi Tanaka; Yoshikazu Yamamura; Tomofumi Santa; Hajime Kotaki; Katsuyoshi Uchi 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 319 KB 👁 1 views

The pharmacokinetics of glycyrrh~n (G) in eight patients with chronic hepatitis receiving chronically i.v. administration of 120 mg dose of G was investigated. The plasma concentration of G in the patients after dosing declined in a monophasic manner. However, the pharmacokinetic profiles varied am

Preliminary pharmacokinetics and safety

Preliminary pharmacokinetics and safety of 882C87 in patients with herpes zoster

✍ Dr. M. J. Wood; M. W. McKendrick; B. Bannister; B. K. Mandal; R. W. Peck; R. J. 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 372 KB

882C87 [I-(p-D-arabinofuranosyl)-5-propynyluracil] is a nucleoside analogue with potent and specific antiviral activity against varicella-zoster virus (VZV). The I C, , of 882C87 against VZV ranges from 0.6 to 3.8 pM. Potentially therapeutic plasma concentrations are readily achieved in humans; the